Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

PURPOSE: To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. METHODS: Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Chadha, Awalpreet S., Skinner, Heath D., Gunther, Jillian R., Munsell, Mark F., Das, Prajnan, Minsky, Bruce D., Delclos, Marc E., Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K., Katz, Matthew H., Fleming, Jason B., Javle, Milind M., Wolff, Robert A., Varadhachary, Gauri R., Crane, Christopher H., Krishnan, Sunil
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2016
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919049/
https://ncbi.nlm.nih.gov/pubmed/27336466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0156910
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki